Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific Advisory Board May 21, 2021 J. Craig Venter, Ph.D. Bluestar Genomics, the developer of an epigenomic platform focused on early cancer detection, has raised $70 million in an oversubscribed Series C equity financing—and named genomics pioneer J. Craig Venter, Ph.D., among two new members of its expanded scientific advisory board. “Collectively, these milestones will extend our ability to deliver on our promise to improve on existing cancer screening and provide a new solution where none exists,” Samuel Levy, Ph.D., Bluestar’s CEO and Chief Scientific Officer, said in a statement.